首页|血清鳞状细胞癌抗原在宫颈癌放化疗预后中的价值研究

血清鳞状细胞癌抗原在宫颈癌放化疗预后中的价值研究

扫码查看
目的 探讨血清鳞状细胞癌抗原(SCC-Ag)水平对宫颈鳞癌根治性同步放化疗患者复发的影响.方法 回顾性分析2015年09月至2022年12月南京市鼓楼医院收治的205例宫颈鳞癌根治性放化疗患者的临床病理资料及治疗前后的SCC-Ag水平,通过受试者工作特征(ROC)曲线分析治疗前及治疗后SCC-Ag水平对复发的影响,并比较不同SCC-Ag水平患者无病生存期(DFS)的差异;采用Logistic回归分析探讨宫颈鳞癌患者放化疗后复发的影响因素.结果 205例患者中,23例复发,182例未复发.治疗前未复发组和复发组的SCC-Ag水平分别为5.99(2.43,16.07)ng/ml和21.97(5.81,39.94)ng/ml,治疗后未复发组和复发组的SCC-Ag水平分别为1.45(1.10,1.89)ng/ml和1.80(1.19,2.43)ng/ml,未复发组患者治疗前及治疗后的SCC-Ag水平比复发组患者低,差异均有统计学意义(P<0.05).ROC曲线分析显示,治疗前SCC-Ag水平预测宫颈鳞癌复发的截断值(cut-off)值为19.06 ng/ml,曲线下面积(AUC)为0.672,灵敏度为0.61,特异度为0.80;治疗后SCC-Ag水平预测宫颈鳞癌复发的cut-off值为1.70 ng/ml,AUC为0.641,灵敏度为0.65,特异度为0.78.以各自的cut-off值将治疗前及治疗后SCC-Ag水平分为高SCC-Ag组和低SCC-Ag组,发现高SCC-Ag组的5年无病生存率明显低于低SCC-Ag组(P<0.05).多因素 Logistic 回归分析显示,肿瘤分期(OR=3.772,95%CI:1.271~11.198,P=0.017)、治疗后 SCC-Ag 水平(OR=1.341,95%CI:1.062~1.694,P=0.014)是宫颈鳞癌根治性放化疗患者复发的独立预测因素.结论 在根治性同步放化疗患者中,治疗前及治疗后的SCC-Ag水平偏高均提示预后不佳,其中肿瘤分期、治疗后SCC-Ag水平是宫颈鳞癌复发的独立预测因素.
Predicative value of serum squamous cell carcinoma antigen level in prognosis of patients with cervical cancer receiving chemoradiotherapy
Objective To explore the effect of serum squamous cell carcinoma antigen(SCC-Ag)on recurrence of cervical cancer patients receiving concurrent chemoradiotherapy.Methods Clinicopathological data and SCC-Ag levels of 205 squamous cervical cancer patients receiving chemoradiation therapy in Nanjing Drum Tower Hospital from September 2015 to December 2022 were analyzed retrospectively.Receiver operator characteristic(ROC)curve was used to analyze the effects of pre-and post-treatment SCC-Ag level on prognosis of cervical cancer patients receiving concurrent chemoradiotherapy,and the difference of disease free survival(DFS)between high level SCC-Ag and low level SCC-Ag were explored.The influencing factors of recurrence in patients with cervical squamous cell carcinoma after radiotherapy and chemotherapy were analyzed using Logistic regression analysis.Results Among the 205 patients,23 relapsed and 182 did not relapse.The levels of SCC-Ag in the non-recurrent group and the recurrent group before treatment were 5.99(2.43,16.07)ng/ml and 21.97(5.81,39.94)ng/ml,respectively.The levels of SCC-Ag in the non-recurrent group and recurrent group after treatment were 1.45(1.10,1.89)ng/ml and 1.80 ng/ml(1.19,2.43)ng/ml,respectively.The levels of SCC-Ag in non-recurrent patients before and after treatment were lower than those in recurrent patients,and the differences were statistically significant(P<0.05).ROC curve showed that the cut-off value of pre-treatment SCC-Ag level was 19.06 ng/ml for predicting recurrence with sensitivity of 0.61,specificity of 0.80 and the area under the curve(ACU)of 0.672.The cut-off value of post-treatment SCC-Ag level was 1.70 ng/ml for predicting recurrence with sensitivity of 0.65,specificity of 0.78 and ACU of 0.641.Pre-and post-treatment SCC-Ag levels were divided into high and low SCC-Ag groups by their own cut-off value,and 5-year disease free survival rates were shorter with statistical significant in high SCC-Ag group compared with low SCC-Ag group(P<0.05).Multivariate Logistic regression analysis showed that tumor stage(OR=3.772,95%CI:1.271-11.198,P=0.017)and post-treatment SCC-Ag level(OR=1.341,95%CI:1.062-1.694,P=0.014)were independent predictors of recurrence in patients with cervical cancer undergoing radical chemoradiotherapy.Conclusion In cervical squamous cell carcinoma patients,high levels of SCC-Ag in both before and after treatment indicate poor prognosis.Among chilinicopathological features,tumor stage and post-treatment SCC-Ag are independent predictors for recurrence in patients with cervical cancer.

Cervical cancerSquamous cell carcinoma antigenPrognosisRisk factors

包金枫、丁美清、常小峰、卢慧、周凡、邓丽萍、闫婧、朱丽晶

展开 >

210000 南京 南京大学医学院附属鼓楼医院肿瘤中心

宫颈癌 血清鳞状细胞癌抗原 预后 危险因素

2024

临床肿瘤学杂志
解放军第八一医院

临床肿瘤学杂志

CSTPCD
影响因子:1.583
ISSN:1009-0460
年,卷(期):2024.29(10)